TVGN

Tevogen BioD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-11

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$15.00

+39.5% vs current

Most likely

Base case

50%

Probability

Target price

$5.50

-48.8% vs current

B-

Bear case

30%

Probability

Target price

$2.00

-81.4% vs current

AI sentiment snapshot

Latest data as of 2026-03-26

AI commentary

Market tone is cautiously constructive after the company regained Nasdaq compliance and announced M&A/LOI activity; coverage remains thin and event-driven, with investor focus on capital discipline and deal execution [#8-K-2026-03-25] [#PR-undated]. Retail/short-term traders may dominate near-term flow given small market cap [#SERP-2].

RankAlpha Sentiment AI - 2026-03-26

Open full AI memo

Evidence flagged

small-cap biotech memo lacks a distinct long-horizon program, partnership, or financing catalyst for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-03-25eventNasdaq minimum bid-price compliance restored (8-K filed)High impact

Tevogen filed an 8-K reporting a material event dated March 20, 2026 and filed 2026-03-25; press releases indicate the company regained compliance with Nasdaq's minimum bid-price requirement, removing a near-term delisting overhang [#8-K-2026-03-25] [#PR-undated].

2027-03-26catalystM&A / generics strategy execution (Apozeal LOI; Sciometrix eval)High impact

Company has announced evaluation/LOI activity to acquire generics assets and has publicly discussed evaluating Sciometrix to support 2026 revenue goals; successful deal(s) or integration could materially re-rate revenue visibility and margins (primary IR/PR disclosures) [#PR-undated].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-03-26 • Updated nightlySource: Internal modelMethodology